These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 38241844

  • 1. Colchicine-intolerant familial mediterranean fever patients: A comparative study between different colchicine doses and IL-1 inhibitor monotherapy.
    Yildirim D, Kardas RC, Gun M, Kaya B, Vasi I, Duran R, Karadeniz H, Avanoglu Guler A, Kucuk H, Erden A, Goker B, Ozturk MA, Tufan A.
    Int Immunopharmacol; 2024 Feb 15; 128():111491. PubMed ID: 38241844
    [Abstract] [Full Text] [Related]

  • 2. Effect of anti-interleukin-1 treatment on quality of life in children with colchicine-resistant familial Mediterranean fever: A single-center experience.
    Kurt T, Aydın F, Nilüfer Tekgöz P, Sezer M, Uncu N, Çelikel Acar B.
    Int J Rheum Dis; 2020 Jul 15; 23(7):977-981. PubMed ID: 32558310
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis.
    Varan Ö, Kucuk H, Babaoglu H, Guven SC, Ozturk MA, Haznedaroglu S, Goker B, Tufan A.
    Mod Rheumatol; 2019 Mar 15; 29(2):363-366. PubMed ID: 29578360
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The Use of Interleukine-1 Inhibitors in Familial Mediterranean Fever Patients: A Narrative Review.
    Hentgen V, Vinit C, Fayand A, Georgin-Lavialle S.
    Front Immunol; 2020 Mar 15; 11():971. PubMed ID: 32670263
    [Abstract] [Full Text] [Related]

  • 6. Comparison of the efficacy and safety of tocilizumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: study protocol for an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial.
    Koga T, Sato S, Miyamoto J, Hagimori N, Kawazoe Y, Arinaga K, Fukushima C, Yamamoto H, Kawakami A.
    Trials; 2018 Dec 29; 19(1):715. PubMed ID: 30594222
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Anti-interleukin-1 treatment in 26 patients with refractory familial mediterranean fever.
    Kucuksahin O, Yildizgoren MT, Ilgen U, Ates A, Kinikli G, Turgay M, Erten S.
    Mod Rheumatol; 2017 Mar 29; 27(2):350-355. PubMed ID: 27328763
    [Abstract] [Full Text] [Related]

  • 11. Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever.
    Şahin A, Derin ME, Albayrak F, Karakaş B, Karagöz Y.
    Adv Rheumatol; 2020 Jan 30; 60(1):12. PubMed ID: 32000860
    [Abstract] [Full Text] [Related]

  • 12. Treatment of colchicine-resistant Familial Mediterranean fever in children and adolescents.
    Eroglu FK, Beşbaş N, Topaloglu R, Ozen S.
    Rheumatol Int; 2015 Oct 30; 35(10):1733-7. PubMed ID: 26001859
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Canakinumab in Children with Familial Mediterranean Fever: A Single-Center, Retrospective Analysis.
    Kisla Ekinci RM, Balci S, Dogruel D, Altintas DU, Yilmaz M.
    Paediatr Drugs; 2019 Oct 30; 21(5):389-395. PubMed ID: 31463794
    [Abstract] [Full Text] [Related]

  • 15. Factors Associated With Successful Withdrawal of Biologic Agents in Children With Colchicine-Resistant Familial Mediterranean Fever.
    Taş Ö, Aydın F, Sezer M, Çelikel Acar B, Bahçeci O, Çakar N, Dumlupınar E, Özçakar ZB.
    J Clin Rheumatol; 2024 Oct 01; 30(7):257-263. PubMed ID: 39226611
    [Abstract] [Full Text] [Related]

  • 16. Successful management of colchicine resistant familial Mediterranean fever patients with a standardized canakinumab treatment protocol: a case series and literature review.
    Eren Akarcan S, Dogantan S, Edeer Karaca N, Aksu G, Kutukculer N.
    Rheumatol Int; 2020 Jan 01; 40(1):161-168. PubMed ID: 31273456
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis.
    Özçakar ZB, Özdel S, Yılmaz S, Kurt-Şükür ED, Ekim M, Yalçınkaya F.
    Clin Rheumatol; 2016 Feb 01; 35(2):441-6. PubMed ID: 25213327
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Anti-interleukin-1 treatment among patients with familial Mediterranean fever resistant to colchicine treatment. Retrospective analysis.
    Sargin G, Kose R, Senturk T.
    Sao Paulo Med J; 2019 May 08; 137(1):39-44. PubMed ID: 31116269
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.